Patents Examined by Chang-Yu Wang
  • Glycosylated PACAP/VIP analogues with enhanced CNS penetration for treatment of neurodegenerative diseases
    Patent number: 10117907
    Abstract: A glycosylated pleiotropic peptide pituitary adenylate cyclase-activating polypeptide (PACAP) which can both agonize PAC1 receptors, causing neuroprotective effects, and antagonize VPAC receptors, causing anti-inflammation in several models of acute neuronal damage and neurodegenerative diseases, including ALS, PD, migraines, and certain forms of dementia, is described. Also described is a method of relieving symptoms of ALS, PD, migraines, and certain forms of dementia, comprising administering to a subject in need thereof an effective amount of a glycosylated PACAP.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: November 6, 2018
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona, a body corporate
    Inventors: Robin Polt, Torsten A E Falk
  • Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies
    Patent number: 10119979
    Abstract: Methods and compositions for treating stroke are disclosed.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: November 6, 2018
    Assignee: Biogen MA Inc.
    Inventors: Jane K. Relton, Humphrey Gardner
  • Methods for reducing corneal nerves damage, corneal lymphangiogenesis or immunity to corneal antigens in dry-eye associated ocular surface diseases by IL-1Ra
    Patent number: 10117906
    Abstract: The invention provides methods and compositions for minimizing, preventing, or treating damage to corneal nerves by administering to a subject with such damage or at risk of exposure to such damage a composition which blocks an activity of an IL-1 cytokine and/or an IL-17 cytokine.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: November 6, 2018
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Reza Dana, Mohammad Dastjerdi, Sunil Chauhan
  • Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
    Patent number: 10112987
    Abstract: Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for Alzheimer's disease. The peptide compositions contain constant domains from human IgG, camelid IgG, and/or shark IgNAR. The peptide compositions include heavy-chain only single-domain antibodies and compositions with one or more variable antigen binding domain bound to one or more constant domains.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: October 30, 2018
    Assignee: ICB INTERNATIONAL, INC.
    Inventors: Ram S. Bhatt, Rishi Bhatt
  • Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
    Patent number: 10112988
    Abstract: Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for Alzheimer's disease. The peptide compositions contain constant domains from human IgG, camelid IgG, and/or shark IgNAR. The peptide compositions include heavy-chain only single-domain antibodies and compositions with one or more variable antigen binding domain bound to one or more constant domains.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: October 30, 2018
    Assignee: ICB INTERNATIONAL, INC.
    Inventors: Ram S. Bhatt, Rishi Bhatt
  • Detection of anti-neurochondrin autoantibody in patients with cerebellar ataxia or cerebellitis
    Patent number: 10112982
    Abstract: Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: October 30, 2018
    Assignee: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
    Inventors: Ramona Miske, Madeleine Scharf, Lars Komorowski, Yvonne Denno, Christian Probst, Inga-Madeleine Dettmann, Winfried Stöcker, Bianca Teegen, Nico Melzer, Heinz Wiendl, Sven Meuth
  • Method for inhibiting or reducing dry eye disease by IL-1Ra
    Patent number: 10105441
    Abstract: The present invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-1 and methods for using this composition to treat inflammatory disease of ocular and adnexal tissues by topical administration. The present invention also discloses devices for delivering this composition to target tissues.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: October 23, 2018
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Reza Dana, Mohammad Dastjerdi
  • Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
    Patent number: 10092591
    Abstract: Disclosed are compositions and methods for inducing therapeutic hypothermia in a subject.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: October 9, 2018
    Assignee: University of Alaska Fairbanks
    Inventors: Kelly Drew, Tulasi Jinka, Lori Bogren, Isaac Bailey, Zachary Carlson, Jasmine Olson
  • Human antibodies to GFR alpha3 and methods of reducing pain associated with GFR alpha3-related diseases
    Patent number: 10077311
    Abstract: The present invention provides antibodies that bind to human GFR?3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFR?3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more GFR?3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: September 18, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Susan D. Croll, Lynn Macdonald, Andrew J. Murphy
  • Methods of diagnosing diseases caused by or associated with neurofibrillary tangles by phosphospecific antibodies recognising Tau
    Patent number: 10066010
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: September 4, 2018
    Assignees: AC IMMUNE S.A., KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Andrea Pfeifer, Andreas Muhs, Maria Pihlgren, Oskar Adolfsson, Fred Van Leuven
  • Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by NRG-2
    Patent number: 10065999
    Abstract: The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: September 4, 2018
    Assignee: Acorda Therapeutics, Inc.
    Inventor: Mark Marchionni
  • Methods of treating amyotrophic lateral sclerosis by HGF
    Patent number: 10058590
    Abstract: The invention presents a therapeutic agent (and progress suppressant) for amyotrophic lateral sclerosis (ALS) containing HGF and/or HGF gene as active ingredient. HGF has an effect of improving the motor function of ALS and life span through two actions, that is, direct neuronutrient factor activity on motoneurons, and indirect improving action of glutamate cytotoxicity on motoneurons by maintaining the level of glutamate transporter in astrocytes. Hence, HGF and/or HGF gene can be used as an effective therapeutic agent not known in the past.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: August 28, 2018
    Assignee: TOSHIKAZU NAKAMURA
    Inventor: Toshikazu Nakamura
  • Biomarkers of autism spectrum disorder
    Patent number: 10060932
    Abstract: Methods for identifying metabolic signatures in blood plasma which are unique to autism are described herein. Samples are analyzed using multiple chromatographic-mass spectrometry-based techniques to orthogonally measure a broad range of small molecular weight metabolites differentially produced in autistic patient samples versus non-autistic control samples. These individual metabolites or a panel of such metabolites serve as metabolic signatures of autism. Such metabolic signatures are used in diagnostic methods to accurately identify individuals with autism spectrum disorder (ASD).
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: August 28, 2018
    Assignee: Stemina Biomarker Discovery, Inc.
    Inventors: Paul West, Robert E. Burrier, Laura Egnash, Alan Smith, Preeti Bais
  • Methods for diagnosis and treatment of amyotrophic lateral sclerosis based on an increased level of interaction between TDP-43 polypeptide and NF-KB P65 polypeptide
    Patent number: 10060933
    Abstract: The present invention provides methods and uses for the diagnostic of a subject predisposed or suspected of developing a neurodegenerative disease or suffering from a neurodegenerative disease. The present invention also relates to methods and uses for identifying candidate compounds and to compounds for treating neurodegenerative disease. The present invention also relates to an animal model for neurodegenerative disease.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: August 28, 2018
    Assignee: UNIVERSITE LAVAL
    Inventors: Jean-Pierre Julien, Vivek Swarup
  • Methods of treating corneal related diseases by corneal endothelial preparation which enables cells to grow in vivo
    Patent number: 10052411
    Abstract: The present invention provides a graft more suitable for the transplantation of corneal endothelial cells and an application method thereof. Specifically, the present invention provides a corneal endothelial preparation capable of cell proliferation in vivo, which contains a substrate and a corneal endothelial cell layer cultured on the substrate, and a treatment method of a disease selected from the group consisting of bullous keratopathy, corneal edema, corneal leukoma and corneal endothelial inflammation, which includes a step of transplanting the preparation to patients. As the substrate, collagen is used.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: August 21, 2018
    Assignee: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Noriko Koizumi, Shigeru Kinoshita, Yuji Sakamoto
  • Red genetically encoded calcium indicators and methods of use
    Patent number: 10053492
    Abstract: Protein indicators useful for calcium imaging, in particular, red genetically-encoded calcium indicators (GECIs) disclosed herein rival best-of-class green GECIs in terms of sensitivity for detecting neural activity, and can be monitored in vivo. The presently-disclosed subject matter further includes a method of monitoring cell activity comprising stimulating a cell comprising a red GECI polypeptide; and detecting fluorescence emitted by the cell.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: August 21, 2018
    Assignee: HOWARD HUGHES MEDICAL INSTITUTE
    Inventors: Douglas S. Kim, Loren L. Looger, Eric R. Schreiter, Karel Svoboda
  • Methods of treating a retinal disease by retinal pigment epithelial stem cells
    Patent number: 10034916
    Abstract: The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention are highly plastic, multipotential stem cells. The invention also includes methods for the treatment of retinal diseases and vision loss involving the transplantation of retinal pigment epithelial stem cells or cells differentiated from retinal pigment epithelial stem cells to the retina of a patient in need of treatment.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: July 31, 2018
    Assignee: Regenerative Research Foundation
    Inventors: Sally Temple, Jeffrey Stern, Enrique L. Salero-Coca
  • Method of immunization for reducing toxic damaged caused by oligomeric form of the amyloid-beta protein with stable amyloid beta monomers and oligomers
    Patent number: 10023622
    Abstract: The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: July 17, 2018
    Assignee: ALZINOVA AB
    Inventors: Torleif Härd, Anders Sandberg
  • Antibodies to tau and methods of treatment therewith
    Patent number: 10011653
    Abstract: Monoclonal antibodies to human tau aggregate, compositions comprising such tau antibodies, and methods of using such tau antibodies for the treatment of neurodegenerative diseases including Alzheimer's disease, Progressive Supranuclear Palsy and Pick's disease.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: July 3, 2018
    Assignee: Eli Lilly and Company
    Inventors: Mansuo Lu Hayashi, Jirong Lu, David Driver, Alberto Alvarado
  • Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
    Patent number: 9988444
    Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: June 5, 2018
    Assignee: PROCLARA BIOSCIENCES, INC.
    Inventors: Richard A. Fisher, Robert George Edward Holgate, Francis Joseph Carr, Timothy David Jones